Aurobindo Pharma gets USFDA nod for anti-diabetes drug

he medicines are indicated as an addition to diet and exercise to improve glycemic control in adults

today said it has received US health regulator's approval to market drug Pioglitazone Tablets in the American market.

The drug firm has received approval from US Food and Drug Administration (USFDA) to manufacture and market Pioglitazone Tablets and its earlier tentatively approved combination of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, Aurobindo Pharma said in a statement.

The products are ready for launch, it added.

The medicines are indicated as an addition to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.

"The combined market size of the products is approximately $2.8 billion for the twelve months ending September 2012 according to IMS," the company said.

Aurobindo now has a total of 177 ANDA approvals (152 final approvals including 2 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA, according to the release.

Shares of Aurobindo were trading at Rs 183.35 on the BSE in afternoon trade, up 1.24% from its previous close

image
Business Standard
177 22
Business Standard

Aurobindo Pharma gets USFDA nod for anti-diabetes drug

he medicines are indicated as an addition to diet and exercise to improve glycemic control in adults

Press Trust of India  |  New Delhi 



today said it has received US health regulator's approval to market drug Pioglitazone Tablets in the American market.

The drug firm has received approval from US Food and Drug Administration (USFDA) to manufacture and market Pioglitazone Tablets and its earlier tentatively approved combination of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, Aurobindo Pharma said in a statement.


The products are ready for launch, it added.

The medicines are indicated as an addition to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.

"The combined market size of the products is approximately $2.8 billion for the twelve months ending September 2012 according to IMS," the company said.

Aurobindo now has a total of 177 ANDA approvals (152 final approvals including 2 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA, according to the release.

Shares of Aurobindo were trading at Rs 183.35 on the BSE in afternoon trade, up 1.24% from its previous close

RECOMMENDED FOR YOU

Aurobindo Pharma gets USFDA nod for anti-diabetes drug

he medicines are indicated as an addition to diet and exercise to improve glycemic control in adults

Aurobindo Pharma today said it has received US health regulator's approval to market anti-diabetes drug Pioglitazone Tablets in the American market.
today said it has received US health regulator's approval to market drug Pioglitazone Tablets in the American market.

The drug firm has received approval from US Food and Drug Administration (USFDA) to manufacture and market Pioglitazone Tablets and its earlier tentatively approved combination of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, Aurobindo Pharma said in a statement.

The products are ready for launch, it added.

The medicines are indicated as an addition to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.

"The combined market size of the products is approximately $2.8 billion for the twelve months ending September 2012 according to IMS," the company said.

Aurobindo now has a total of 177 ANDA approvals (152 final approvals including 2 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA, according to the release.

Shares of Aurobindo were trading at Rs 183.35 on the BSE in afternoon trade, up 1.24% from its previous close
image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard